Implexion Pharma develops innovative strategies to treat selected diseases by targeting gut microbial production of disease-causing substances.
Implexion's first drug candidate is developed against the orphan drug-classified disease primary sclerosing cholangitis (PSC). Today there is no medical treatment for PSC and the patient needs liver transplantation to prevent premature death. Implexion's therapies have a unique opportunity to treat patients and prolong life, and we have treatments for several other indications in early pipeline.
Company Details
- Founded
- -
- Address
- Erik Dahlbergsgatan 11 B, Göteborg,västra Götaland County 411 26,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://implexion.se/
- HQ
- Göteborg, Västra Götaland County
Implexion Pharma Questions
Implexion Pharma's website is https://implexion.se/
Implexion Pharma's LinkedIn profile is https://se.linkedin.com/company/implexion-pharma
Implexion Pharma's industry is
Biotechnology Research
Implexion Pharma's top competitors are
Biotech-Igg,
Abboxia,
Lithea Ab (Former Moroxite T Ab),
Innate Pharmaceuticals Ab,
Junvik Consulting,
Gain Pharmaceuticals,
Rare Thyroid Therapeutics,
Morenco Pharma Ab,
Pharmacure Health Care International Ab,
Eribis Pharmaceuticals.
Implexion Pharma's categories are Biotechnology Research
Implexion Pharma's founding year is 2019
